Trovafloxacin (BioDeep_00000006573)
Secondary id: BioDeep_00001868376
human metabolite blood metabolite
代谢物信息卡片
7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
化学式: C20H15F3N4O3 (416.1096)
中文名称: 聚苯乙烯磺酸钙
谱图信息:
最多检出来源 Mus musculus(blood) 10.5%
分子结构信息
SMILES: C1C2C(C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
InChI: InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
描述信息
Trovafloxacin (sold as Trovan by Pfizer) is a broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was withdrawn from the market due to the risk of hepatotoxicity. It had better gram-positive bacterial coverage and less gram-negative coverage than the previous fluoroquinolones. [Wikipedia]
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
D004791 - Enzyme Inhibitors
同义名列表
6 个代谢物同义名
7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-Amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate; Trovafloxacin; MLS000080907; TVFX; Trovafloxacin
数据库引用编号
18 个数据库交叉引用编号
- ChEBI: CHEBI:9763
- KEGG: C07664
- KEGGdrug: D08654
- PubChem: 481696
- PubChem: 62959
- HMDB: HMDB0014823
- Metlin: METLIN66709
- DrugBank: DB00685
- ChEMBL: CHEMBL428
- Wikipedia: Trovafloxacin
- chemspider: 56670
- CAS: 147059-72-1
- PMhub: MS000019635
- PubChem: 9866
- PDB-CCD: TR6
- NIKKAJI: J785.495A
- RefMet: Trovafloxacin
- KNApSAcK: 9763
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Giulio Giustarini, Nienke Vrisekoop, Laura Kruijssen, Laura Wagenaar, Selma van Staveren, Manon van Roest, Rob Bleumink, Marianne Bol-Schoenmakers, Richard J Weaver, Leo Koenderman, Joost Smit, Raymond Pieters. Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement.
Toxicological sciences : an official journal of the Society of Toxicology.
2019 02; 167(2):385-396. doi:
10.1093/toxsci/kfy244. [PMID: 30247740] - Yu-Hsin Chiu, Xueyao Jin, Christopher B Medina, Susan A Leonhardt, Volker Kiessling, Brad C Bennett, Shaofang Shu, Lukas K Tamm, Mark Yeager, Kodi S Ravichandran, Douglas A Bayliss. A quantized mechanism for activation of pannexin channels.
Nature communications.
2017 01; 8(?):14324. doi:
10.1038/ncomms14324. [PMID: 28134257] - Nuggehally R Srinivas. Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion.
Xenobiotica; the fate of foreign compounds in biological systems.
2016 Sep; 46(9):784-92. doi:
10.3109/00498254.2015.1121554. [PMID: 26711252] - Jingtao Lu, Shannon Einhorn, Lata Venkatarangan, Manda Miller, David A Mann, Paul B Watkins, Edward LeCluyse. Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing.
Toxicological sciences : an official journal of the Society of Toxicology.
2015 Sep; 147(1):39-54. doi:
10.1093/toxsci/kfv117. [PMID: 26092927] - Adnan H Mahmood, Xin Liu, Jeffrey E Grice, Gregory A Medley, Michael S Roberts. Using deconvolution to understand the mechanism for variable plasma concentration-time profiles after intramuscular injection.
International journal of pharmaceutics.
2015 Mar; 481(1-2):71-8. doi:
10.1016/j.ijpharm.2015.01.046. [PMID: 25636300] - Keiyu Oshida, Naresh Vasani, Russell S Thomas, Dawn Applegate, Mitch Rosen, Barbara Abbott, Christopher Lau, Grace Guo, Lauren M Aleksunes, Curtis Klaassen, J Christopher Corton. Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.
PloS one.
2015; 10(2):e0112655. doi:
10.1371/journal.pone.0112655. [PMID: 25689681] - Kyle L Poulsen, Jesus Olivero-Verbel, Kevin M Beggs, Patricia E Ganey, Robert A Roth. Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.
The Journal of pharmacology and experimental therapeutics.
2014 Jul; 350(1):164-70. doi:
10.1124/jpet.114.214189. [PMID: 24817034] - Kyle L Poulsen, Ryan P Albee, Patricia E Ganey, Robert A Roth. Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.
The Journal of pharmacology and experimental therapeutics.
2014 May; 349(2):185-91. doi:
10.1124/jpet.113.211276. [PMID: 24525298] - Ivan K H Poon, Yu-Hsin Chiu, Allison J Armstrong, Jason M Kinchen, Ignacio J Juncadella, Douglas A Bayliss, Kodi S Ravichandran. Unexpected link between an antibiotic, pannexin channels and apoptosis.
Nature.
2014 Mar; 507(7492):329-34. doi:
10.1038/nature13147. [PMID: 24646995] - Daphna Laifenfeld, Luping Qiu, Rachel Swiss, Jennifer Park, Michael Macoritto, Yvonne Will, Husam S Younis, Michael Lawton. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.
Toxicological sciences : an official journal of the Society of Toxicology.
2014 Jan; 137(1):234-48. doi:
10.1093/toxsci/kft232. [PMID: 24136188] - Adnan H Mahmood, Gregory A Medley, Jeffrey E Grice, Xin Liu, Michael S Roberts. Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection.
Journal of pharmaceutical and biomedical analysis.
2012 Mar; 62(?):220-3. doi:
10.1016/j.jpba.2012.01.007. [PMID: 22305082] - Renaud Respaud, Solene Grayo, Eric Singlas, Sophie Dubouch, Alban Le Monnier, Marie-Catherine Lott. High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis.
Journal of analytical methods in chemistry.
2012; 2012(?):436349. doi:
10.1155/2012/436349. [PMID: 22567560] - V Talla, Pr Veerareddy. Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.
Journal of young pharmacists : JYP.
2011 Oct; 3(4):304-9. doi:
10.4103/0975-1483.90242. [PMID: 22224037] - Woo Hyuk Jang, Dong Hoon Yoo, Seong Woon Park. Prevalence of and Risk Factors for Levofloxacin-Resistant E. coli Isolated from Outpatients with Urinary Tract Infection.
Korean journal of urology.
2011 Aug; 52(8):554-9. doi:
10.4111/kju.2011.52.8.554. [PMID: 21927703] - Yuan-Chuen Wang, Wan-Yu Li, Deng-Chyang Wu, Jeh-Jeng Wang, Cheng-Hsun Wu, Jyun-Ji Liao, Cheng-Kun Lin. In Vitro Activity of 2-methoxy-1,4-naphthoquinone and Stigmasta-7,22-diene-3β-ol from Impatiens balsamina L. against Multiple Antibiotic-Resistant Helicobacter pylori.
Evidence-based complementary and alternative medicine : eCAM.
2011; 2011(?):704721. doi:
10.1093/ecam/nep147. [PMID: 19773391] - Xia-Hong Dai, Pan Zhang, Mei-Fang Xiao, Rong-Rong Zhou, Bao-Xin Zhang, Guan-Sheng Hu, Ze-Bing Huang, Xue-Gong Fan. Protective role of α2HS-glycoprotein in HBV-associated liver failure.
International journal of molecular sciences.
2011; 12(6):3846-56. doi:
10.3390/ijms12063846. [PMID: 21747711] - Shuyu Xie, Luyan Zhu, Zhao Dong, Yan Wang, Xiaofang Wang, WenZhong Zhou. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.
International journal of nanomedicine.
2011; 6(?):547-55. doi:
10.2147/ijn.s17083. [PMID: 21468357] - J Garau, A Fritsch, P Arvis, R C Read. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
Journal of chemotherapy (Florence, Italy).
2010 Aug; 22(4):264-6. doi:
10.1179/joc.2010.22.4.264. [PMID: 20685631] - Patrick J Shaw, Kevin M Beggs, Erica M Sparkenbaugh, Christine M Dugan, Patricia E Ganey, Robert A Roth. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.
Toxicological sciences : an official journal of the Society of Toxicology.
2009 Oct; 111(2):288-301. doi:
10.1093/toxsci/kfp163. [PMID: 19638433] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - Patrick J Shaw, Patricia E Ganey, Robert A Roth. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.
The Journal of pharmacology and experimental therapeutics.
2009 Jul; 330(1):72-8. doi:
10.1124/jpet.109.151068. [PMID: 19351866] - Patrick J Shaw, Aaron M Fullerton, Michael A Scott, Patricia E Ganey, Robert A Roth. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability.
Toxicology and applied pharmacology.
2009 May; 236(3):293-300. doi:
10.1016/j.taap.2009.01.018. [PMID: 19367693] - Patrick J Shaw, Amy C Ditewig, Jeffrey F Waring, Michael J Liguori, Eric A Blomme, Patricia E Ganey, Robert A Roth. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.
Toxicological sciences : an official journal of the Society of Toxicology.
2009 Jan; 107(1):270-80. doi:
10.1093/toxsci/kfn205. [PMID: 18930950] - Patrick J Shaw, Patricia E Ganey, Robert A Roth. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.
The Journal of pharmacology and experimental therapeutics.
2009 Jan; 328(1):62-8. doi:
10.1124/jpet.108.143792. [PMID: 18820134] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Markus Zeitlinger, Robert Sauermann, Manfred Fille, Johann Hausdorfer, Irmgard Leitner, Markus Müller. Plasma protein binding of fluoroquinolones affects antimicrobial activity.
The Journal of antimicrobial chemotherapy.
2008 Mar; 61(3):561-7. doi:
10.1093/jac/dkm524. [PMID: 18216178] - Patrick J Shaw, Marie J Hopfensperger, Patricia E Ganey, Robert A Roth. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
Toxicological sciences : an official journal of the Society of Toxicology.
2007 Nov; 100(1):259-66. doi:
10.1093/toxsci/kfm218. [PMID: 17709330] - Jeffrey F Waring, Michael J Liguori, James P Luyendyk, Jane F Maddox, Patricia E Ganey, Robert F Stachlewitz, Colin North, Eric A G Blomme, Robert A Roth. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils.
The Journal of pharmacology and experimental therapeutics.
2006 Mar; 316(3):1080-7. doi:
10.1124/jpet.105.096347. [PMID: 16299187] - Megan Nguyen, Eunice P Chung. Telithromycin: the first ketolide antimicrobial.
Clinical therapeutics.
2005 Aug; 27(8):1144-63. doi:
10.1016/j.clinthera.2005.08.009. [PMID: 16199242] - Laurel C Preheim, Keith M Olsen, Mei Yue, Mary U Snitily, Martha J Gentry-Nielsen. Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia.
Diagnostic microbiology and infectious disease.
2005 Feb; 51(2):103-11. doi:
10.1016/j.diagmicrobio.2004.09.008. [PMID: 15698715] - Gary E Stein, Sharon Schooley. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
International journal of antimicrobial agents.
2004 Aug; 24(2):168-72. doi:
10.1016/j.ijantimicag.2004.01.013. [PMID: 15288316] - E Azoulay-Dupuis, J P Bédos, J Mohler, G Peytavin, R Isturiz, P Moine, V Rieux, C Cherbuliez, J C Péchère, B Fantin, T Köhler. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Antimicrobial agents and chemotherapy.
2004 Mar; 48(3):765-73. doi:
10.1128/aac.48.3.765-773.2004. [PMID: 14982762] - Hans-Jörg Linde, Norbert Lehn. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
The Journal of antimicrobial chemotherapy.
2004 Feb; 53(2):252-7. doi:
10.1093/jac/dkh036. [PMID: 14688048] - James R Gavin, Rolf Kubin, Shurjeel Choudhri, Dagmar Kubitza, Hebert Himmel, Rainer Gross, Jutta M Meyer. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
Drug safety.
2004; 27(9):671-86. doi:
10.2165/00002018-200427090-00005. [PMID: 15230648] - Irina S Barequet, Paul Denton, Gerard J Osterhout, Suhas Tuli, Terrence P O'Brien. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Archives of ophthalmology (Chicago, Ill. : 1960).
2004 Jan; 122(1):65-9. doi:
10.1001/archopht.122.1.65. [PMID: 14718297] - Archie C Perry, Branko Prpa, Mark S Rouse, Kerryl E Piper, Arlen D Hanssen, James M Steckelberg, Robin Patel. Levofloxacin and trovafloxacin inhibition of experimental fracture-healing.
Clinical orthopaedics and related research.
2003 Sep; ?(414):95-100. doi:
10.1097/01.blo.0000087322.60612.14. [PMID: 12966282] - A Lubasch, S Ziege, B Brodersen, K Borner, P Koeppe, H Lode. Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2003 Jul; 9(7):670-7. doi:
10.1046/j.1469-0691.2003.00644.x. [PMID: 12925107] - A Dalhoff, F-J Schmitz. In vitro antibacterial activity and pharmacodynamics of new quinolones.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
2003 Apr; 22(4):203-21. doi:
10.1007/s10096-003-0907-5. [PMID: 12687416] - José Luis Vílchez, Jalila Taoufiki, Lilia Araujo, Alberto Navalón. Determination of the antibacterial trovafloxacin by differential-pulse adsorptive stripping voltammetry.
Journal of pharmaceutical and biomedical analysis.
2003 Mar; 31(3):465-71. doi:
10.1016/s0731-7085(02)00713-6. [PMID: 12615233] - Kelly A Sprandel, Keith A Rodvold. Safety and tolerability of fluoroquinolones.
Clinical cornerstone.
2003; Suppl 3(?):S29-36. doi:
10.1016/s1098-3597(03)90027-5. [PMID: 14992418] - Gloria García-Calvo, Araceli Parra, Carmen Ponte, Francisco Soriano, María J Giménez, Lorenzo Aguilar. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
International journal of antimicrobial agents.
2002 Dec; 20(6):477-80. doi:
10.1016/s0924-8579(02)00242-x. [PMID: 12458147] - A Calvo, M J Giménez, L Alou, M L Gómez-Lus, L Aguilar, J Prieto. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
International journal of antimicrobial agents.
2002 Aug; 20(2):144-6. doi:
10.1016/s0924-8579(02)00119-x. [PMID: 12297365] - Hairui Liang, Michael B Kays, Kevin M Sowinski. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2002 May; 772(1):53-63. doi:
10.1016/s1570-0232(02)00046-6. [PMID: 12016015] - Daniel P Healy, Paul A Silverman, Alice N Neely, Ian Alan Holder, George E Babcock. Effect of antibiotics on polymorphonuclear neutrophil apoptosis.
Pharmacotherapy.
2002 May; 22(5):578-85. doi:
10.1592/phco.22.8.578.33217. [PMID: 12013356] - John C Williamson, David W Craft, John D Butts, Ralph H Raasch. In vitro assessment of urinary isolates of ampicillin-resistant enterococci.
The Annals of pharmacotherapy.
2002 Feb; 36(2):246-50. doi:
10.1345/aph.1a085. [PMID: 11847942] - George G Zhanel, Kelly Ennis, Lavern Vercaigne, Andrew Walkty, Alfred S Gin, John Embil, Heather Smith, Daryl J Hoban. A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs.
2002; 62(1):13-59. doi:
10.2165/00003495-200262010-00002. [PMID: 11790155] - Caroline M Perry, Douglas Ormrod, Miriam Hurst, Susan V Onrust. Gatifloxacin: a review of its use in the management of bacterial infections.
Drugs.
2002; 62(1):169-207. doi:
10.2165/00003495-200262010-00007. [PMID: 11790160] - L R Baden, G Horowitz, H Jacoby, G M Eliopoulos. Quinolones and false-positive urine screening for opiates by immunoassay technology.
JAMA.
2001 Dec; 286(24):3115-9. doi:
10.1001/jama.286.24.3115. [PMID: 11754677] - P Joyanes, A Pascual, M J Giménez, I García, L Aguilar, E Perea. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
Chemotherapy.
2001 Dec; 47(6):409-14. doi:
10.1159/000048551. [PMID: 11786655] - J M Kushner, H J Peckman, C R Snyder. Seizures associated with fluoroquinolones.
The Annals of pharmacotherapy.
2001 Oct; 35(10):1194-8. doi:
10.1345/aph.10359. [PMID: 11675843] - C Urban, N Rahman, X Zhao, N Mariano, S Segal-Maurer, K Drlica, J J Rahal. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
The Journal of infectious diseases.
2001 Sep; 184(6):794-8. doi:
10.1086/323086. [PMID: 11517444] - J Prieto, L Aguilar, F Fuentes, M J Giménez, L Alou, R Dal-Ré, F Sörgel, J Frías. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
International journal of antimicrobial agents.
2001 Sep; 18(3):231-8. doi:
10.1016/s0924-8579(01)00392-2. [PMID: 11673035] - J A Ocaña, M Callejón, F J Barragán. Determination of trovafloxacin in human serum by time resolved terbium-sensitised luminescence.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2001 Jun; 13(3):297-301. doi:
10.1016/s0928-0987(01)00116-6. [PMID: 11384852] - R J Carman, M A Woodburn. Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora.
Regulatory toxicology and pharmacology : RTP.
2001 Jun; 33(3):276-84. doi:
10.1006/rtph.2001.1473. [PMID: 11407931] - G García-Calvo, A Parra, L Aguilar, C Ponte, M J Giménez, A Carcas, M Kinzig-Schippers, F Soriano. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.
Antimicrobial agents and chemotherapy.
2001 Jun; 45(6):1876-8. doi:
10.1128/aac.45.6.1876-1878.2001. [PMID: 11353641] - L E Stearne, I C Gyssens, W H Goessens, J W Mouton, W J Oyen, J W van der Meer, H A Verbrugh. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Antimicrobial agents and chemotherapy.
2001 May; 45(5):1394-401. doi:
10.1128/aac.45.5.1394-1401.2001. [PMID: 11302801] - F López Fornas, F Martínez García, J Pérez Salmeron, D Roldán Conesa, R Cortés Sanchez, A García Alberola, J Ruíz Gómez, J Gómez Gómez, M Valdés Chávarri. Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy.
2001 May; 47(5):623-9. doi:
10.1093/jac/47.5.623. [PMID: 11328774] - R Thiel, S Metzner, C Gericke, U Rahm, R Stahlmann. Effects of fluoroquinolones on the locomotor activity in rats.
Archives of toxicology.
2001 Mar; 75(1):36-41. doi:
10.1007/s002040000207. [PMID: 11357519] - G Garcia-Calvo, A Molleja, M J Giménez, A Parra, E Nieto, C Ponte, L Aguilar, F Soriano. Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers.
Antimicrobial agents and chemotherapy.
2001 Feb; 45(2):608-11. doi:
10.1128/aac.45.2.608-611.2001. [PMID: 11158764] - D B Huang, Z D Jiang, C D Ericsson, J Adachi, H L Dupont. Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico.
Scandinavian journal of infectious diseases.
2001; 33(11):812-4. doi:
10.1080/00365540110076589. [PMID: 11760159] - J A Balfour, D P Figgitt. Telithromycin.
Drugs.
2001; 61(6):815-29; discussion 830. doi:
10.2165/00003495-200161060-00016. [PMID: 11398913] - I Morrissey, J T George. Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method.
International journal of antimicrobial agents.
2001 Jan; 17(1):33-7. doi:
10.1016/s0924-8579(00)00321-6. [PMID: 11137646] - M Purswani, S Eckert, H Arora, R Johann-Liang, G J Noel. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin.
The Journal of antimicrobial chemotherapy.
2000 Dec; 46(6):921-9. doi:
10.1093/jac/46.6.921. [PMID: 11102411] - K G Naber, K Hollauer, D Kirchbauer, W Witte. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
International journal of antimicrobial agents.
2000 Nov; 16(3):239-43. doi:
10.1016/s0924-8579(00)00222-3. [PMID: 11091042] - W Ng, K Olsen, I Lutsar, L Wubbel, F Ghaffar, H Jafri, G H McCracken, I R Friedland. Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
2000 Nov; 108(11):729-33. doi:
10.1034/j.1600-0463.2000.d01-21.x. [PMID: 11211965] - J McNabb, R Quintiliani, C H Nightingale, D P Nicolau. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
Chemotherapy.
2000 Nov; 46(6):383-9. doi:
10.1159/000007318. [PMID: 11053903] - A A Khan, T R Slifer, F G Araujo, Y Suzuki, J S Remington. Protection against lipopolysaccharide-induced death by fluoroquinolones.
Antimicrobial agents and chemotherapy.
2000 Nov; 44(11):3169-73. doi:
10.1128/aac.44.11.3169-3173.2000. [PMID: 11036044] - P D Holtom, S A Pavkovic, P D Bravos, M J Patzakis, L E Shepherd, B Frenkel. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
2000 Sep; 18(5):721-7. doi:
10.1002/jor.1100180507. [PMID: 11117292] - I Odenholt, T Cars, E Lowdin. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
The Journal of antimicrobial chemotherapy.
2000 Jul; 46(1):35-43. doi:
10.1093/jac/46.1.35. [PMID: 10882686] - S Gollapudi, S Gupta, H Thadepalli. Salmonella typhimurium-induced reactivation of latent HIV-1 in promonocytic U1 cells is inhibited by trovafloxacin.
International journal of molecular medicine.
2000 Jun; 5(6):615-8. doi:
10.3892/ijmm.5.6.615. [PMID: 10812011] - J S Bradley, G L Kearns, M D Reed, E V Capparelli, J Vincent. Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Antimicrobial agents and chemotherapy.
2000 May; 44(5):1195-9. doi:
10.1128/aac.44.5.1195-1199.2000. [PMID: 10770751] - D E King, R Malone, S H Lilley. New classification and update on the quinolone antibiotics.
American family physician.
2000 May; 61(9):2741-8. doi:
NULL. [PMID: 10821154] - E J Giamarellou-Bourboulis, H Sambatakou, P Grecka, Z Chryssouli, H Giamarellou. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus.
Diagnostic microbiology and infectious disease.
1999 Aug; 34(4):301-7. doi:
10.1016/s0732-8893(99)00044-9. [PMID: 10459481] - K Goel, D Menzies, B A Cunha. Elevated international normalized ratio associated with trovafloxacin.
Annals of internal medicine.
1999 Jul; 131(1):72. doi:
10.7326/0003-4819-131-1-199907060-00024. [PMID: 10391825] - L Alou, M L Anta, M G Del Potro, F Fuentes, I P Balcabao, M L Gomez-Lus, J Prieto. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
International journal of antimicrobial agents.
1999 Jul; 12(2):135-9. doi:
10.1016/s0924-8579(99)00062-x. [PMID: 10418758] - K Borner, H Hartwig, H Lode. Determination of trovafloxacin in human body fluids by high-performance liquid chromatography.
Journal of chromatography. A.
1999 Jun; 846(1-2):175-80. doi:
10.1016/s0021-9673(99)00247-2. [PMID: 10420609] - W Ng, I Lutsar, L Wubbel, F Ghaffar, H Jafri, G H McCracken, I R Friedland. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
The Journal of antimicrobial chemotherapy.
1999 Jun; 43(6):811-6. doi:
10.1093/jac/43.6.811. [PMID: 10404320] - L C Preheim, K M Olsen, M Yue, M U Snitily, M J Gentry. Ethanol feeding does not affect the efficacy or pharmacokinetics of azithromycin, trovafloxacin, or ceftriaxone in a rat model of pneumococcal pneumonia.
Alcoholism, clinical and experimental research.
1999 May; 23(5):842-9. doi:
. [PMID: 10371404] - C C McCoig, L Wubbel, H S Jafri, I Lutsar, R Bastero, K Olsen, S Shelton, I R Friedland, G H McCracken. Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.
The Journal of antimicrobial chemotherapy.
1999 May; 43(5):683-8. doi:
10.1093/jac/43.5.683. [PMID: 10382890] - P D Lister, C C Sanders. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Antimicrobial agents and chemotherapy.
1999 May; 43(5):1118-23. doi:
10.1128/aac.43.5.1118. [PMID: 10223923] - E B Breitschwerdt, M G Papich, B C Hegarty, B Gilger, S I Hancock, M G Davidson. Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs.
Antimicrobial agents and chemotherapy.
1999 Apr; 43(4):813-21. doi:
10.1128/aac.43.4.813. [PMID: 10103185] - A A Alghasham, M C Nahata. Trovafloxacin: a new fluoroquinolone.
The Annals of pharmacotherapy.
1999 Jan; 33(1):48-60. doi:
10.1345/aph.17460. [PMID: 9972385] - A B Onderdonk. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
American journal of surgery.
1998 Dec; 176(6A Suppl):39S-45S. doi:
10.1016/s0002-9610(98)00219-0. [PMID: 9935256] - C H van Nispen, A I Hoepelman, M Rozenberg-Arska, J Verhoef, L Purkins, S A Willavize. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers.
American journal of surgery.
1998 Dec; 176(6A Suppl):27S-31S. doi:
10.1016/s0002-9610(98)00217-7. [PMID: 9935254] - J Vincent, T Hunt, R Teng, L Robarge, S A Willavize, H L Friedman. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
American journal of surgery.
1998 Dec; 176(6A Suppl):32S-38S. doi:
10.1016/s0002-9610(98)00218-9. [PMID: 9935255] - J Vincent, R Teng, D K Dalvie, H L Friedman. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
American journal of surgery.
1998 Dec; 176(6A Suppl):8S-13S. doi:
10.1016/s0002-9610(98)00213-x. [PMID: 9935250] - G Melnik, W H Schwesinger, L C Dogolo, R Teng, J Vincent. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery.
American journal of surgery.
1998 Dec; 176(6A Suppl):14S-17S. doi:
10.1016/s0002-9610(98)00214-1. [PMID: 9935251] - M G Martens, M Maccato, C Van Hook, J Vincent. Penetration of trovafloxacin into gynecologic tissues.
American journal of surgery.
1998 Dec; 176(6A Suppl):18S-22S. doi:
10.1016/s0002-9610(98)00215-3. [PMID: 9935252] - J Vincent, R Teng, S M Pelletier, S A Willavize, H L Friedman. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
American journal of surgery.
1998 Dec; 176(6A Suppl):23S-26S. doi:
10.1016/s0002-9610(98)00216-5. [PMID: 9935253] - A J Fischman, J W Babich, A A Bonab, N M Alpert, J Vincent, R J Callahan, J A Correia, R H Rubin. Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.
Antimicrobial agents and chemotherapy.
1998 Aug; 42(8):2048-54. doi:
10.1128/aac.42.8.2048. [PMID: 9687405] - E W Ng, N Samiy, K L Ruoff, F V Cousins, D C Hooper, S von Gunten, D J D'Amico, A S Baker. Treatment of experimental Staphylococcus epidermidis endophthalmitis with oral trovafloxacin.
American journal of ophthalmology.
1998 Aug; 126(2):278-87. doi:
10.1016/s0002-9394(98)00157-3. [PMID: 9727522] - G Melnik, W H Schwesinger, R Teng, L C Dogolo, J Vincent. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
1998 Jun; 17(6):424-6. doi:
10.1007/bf01691576. [PMID: 9758286] - J Vincent, L Dogolo, B A Baris, S A Willavize, R Teng. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
1998 Jun; 17(6):427-30. doi:
10.1007/bf01691577. [PMID: 9758287] - L Purkins, S D Oliver, S A Willavize. An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
1998 Jun; 17(6):431-3. doi:
10.1007/bf01691578. [PMID: 9758288] - J P Bédos, V Rieux, J Bauchet, M Muffat-Joly, C Carbon, E Azoulay-Dupuis. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Antimicrobial agents and chemotherapy.
1998 Apr; 42(4):862-7. doi:
10.1128/aac.42.4.862. [PMID: 9559797] - J Z Montgomerie, D G Schick. Treatment of enterococcal pyelonephritis with trovafloxacin and rifampin: in vitro-in vivo contrast.
Antimicrobial agents and chemotherapy.
1998 Jan; 42(1):188-9. doi:
10.1128/aac.42.1.188. [PMID: 9449285] - H Thadepalli, S K Chuah, U Reddy, N Hanna, R Clark, R J Polzer, S Gollapudi. Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.
Antimicrobial agents and chemotherapy.
1997 Sep; 41(9):1933-6. doi:
10.1128/aac.41.9.1933. [PMID: 9303387] - J M Andrews, D Honeybourne, N P Brenwald, D Bannerjee, M Iredale, B Cunningham, R Wise. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy.
The Journal of antimicrobial chemotherapy.
1997 Jun; 39(6):797-802. doi:
10.1093/jac/39.6.797. [PMID: 9222050] - N R Cutler, J Vincent, S S Jhee, R Teng, T Wardle, G Lucas, L C Dogolo, J J Sramek. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.
Antimicrobial agents and chemotherapy.
1997 Jun; 41(6):1298-300. doi:
10.1128/aac.41.6.1298. [PMID: 9174187]
